Clinical Trials Logo

Essential Thrombocytosis clinical trials

View clinical trials related to Essential Thrombocytosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02158858 Active, not recruiting - Leukemia Clinical Trials

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Start date: July 16, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1 Part (Complete): Open-label, sequential dose escalation study of pelabresib in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis. Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.